Effectiveness and safety of once-daily aminoglycosides: A meta-analysis

American Journal of Health-System Pharmacy

Volumn 53, Issue 10, 1996, Pages 1141-1150

  Ferriols Lisart, Rafael ^a   Alós Almińana, Manuel ^b,c  

^a HOSPITAL GENERAL DE CASTELLÓN   (Spain)

^b HG   (Netherlands)

^c UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Aminoglycosides; Clinical studies; Dosage schedules; Drugs, clinical effectiveness; Toxicity

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AMPICILLIN; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CLOXACILLIN; GENTAMICIN; METRONIDAZOLE; NETILMICIN; PENICILLIN G; PIPERACILLIN; TINIDAZOLE; TOBRAMYCIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; HUMAN; INFECTION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; META ANALYSIS; NEPHROTOXICITY; OTOTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0029879960     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/53.10.1141     Document Type: Article

References (103)

1. Gilbert DV. Once-daily aminoglycoside therapy. Antimicrob Agents Chemother. 1991; 35:399-405.
2. Sharon MW, Dasta JF. Aminoglycoside dosing considerations in intensive care unit patients. Ann Pharmacother. 1993; 27:351-7.
3. Barriere SL. Aminoglycosides: a re-assessment of their therapeutic role. Clin Pharm. 1988; 7:385-90.
4. Mattie H, Craig WA, Pechère JC. Determinants of efficacy and toxicity of aminoglycosides. J Antimicrob Chemother. 1989; 24:281-93.
5. Spivey MJ The postantibiotic effect. Clin Pharm. 1992; 11:865-75.
6. Zhannel GG, Craig WA. Pharmacokinetic contributions to postantibiotic effects. Focus on aminoglycosides. Clin Pharmacokinet. 1994; 27:377-92.
7. Verpooten GA, Giuliano RA, Verbist L et al. Once-daily dosing decreases renal accumulation of gentamicin and netilmicin. Clin Pharmacol Ther. 1989; 45:22-6.
8. De Broe ME, Verbist L, Verpooten GA. Influence of dosage schedule on renal cortical accumulation of amikacin and tobramycin in man. J Antimicrob Chemother. 1991; 27(suppl C):41-7.
9. Pechère JC, Craig WA, Meunier F. Once daily dosing of aminoglycoside: one step forward. J Antimicrob Chemother. 1991; 27(suppl C):149-52.
10. Nordström L, Lerner SA. Single daily dose therapy with aminoglycosides. J Hosp Infect. 1991; 18(suppl A):117-29.
11. Felson DT. Bias in meta-analytic research. J Clin Epidemiol. 1992; 45:885-92.
12. Chalmers TC, Smith H Jr, Blackburn B et al. A method for assessing the quality of randomized controlled trials. Control Clin Trials. 1981; 2:31-49.
13. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959; 22:719-48.
14. Fleiss JL. Statistical methods for rates and proportions. 2nd ed. New York: Wiley; 1981.
15. Mehta CR, Patel NR, Gray R. Computing an exact confidence interval for common odds ratio in several 2x2 contingency tables. J Am Stat Assoc. 1985; 80:969-73.
16. Einarson TR, Leeder JS, Koren G. A method for meta-analysis of epidemiological studies. Drug Intell Clin Pharm. 1988: 22:813-24.
17. Einarson TR, McGhan WF, Bootman JL et al. Meta-analysis: quantitative integration of independent research results. Am J Hosp Pharm. 1985; 42:1957-64.
18. Kapusnik JE, Hackbarth CJ, Chambers HF et al. Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental pseudomonas pneumonia. J Infect Dis. 1988; 158(1):7-12.
19. Herscovici L, Grise G, Thauvin C et al. Efficacy and safety of once daily versus intermittent dosing of tobramycin in rabbits with acute pyelonephritis. Scand J Infect Dis. 1988; 20:205-12.
20. Reiner NE, Bioxham DD, Thompson WL. Nephrotoxicity of gentamicin and tobramycin given once daily or continuously in dogs. J Antimicrob Chemother. 1978; 4(suppl A):85-101.
21. Salen-Mghir A, Cremieux AC, Vallois JM et al. Optimal aminoglycoside dosing regimen for penicllin-tobiamycln synergism in experimental Streptococcus adjacens endocarditis. Antimicrob Agents Chemother. 1992; 36:2403-7.
22. McGrath BJ, Bailey EM, Lamp KC et al. Pharmacodynamics of once-daily amikacin in various combinations with cefepime, aztreonam, and ceftazidime against Pseudomonas aemginosa in an in vitro infection model. Antimicrob Agents Chemother. 1992; 36:2741-6.
23. Takumida M, Nishida I, Nikaido M et al. Effect of dosing schedule on aminoglycoside ototoxicity: comparative cochlear ototoxicity of amikacin and isepamicin. ORL. J Otorhinolaryngol Relat Spec. 1990; 52:341-9.
24. Pettorossi VE, Ferraresi A, Errico P et al. The impact of different dosing regimens of the aminoglycosides netilmicin and amikacin on vestibulotoxicity in the guinea pig. Eur Arch Otorhinolaryngol. 1990; 247:277-82.
25. Gerber AU, Kozak S, Segessenman C et al. Once-daily versus thrice-daily administration of netilmicin in combination therapy of Pseudomonas aeruginosa infection in a man-adapted neutropenic animal model. Eur J Clin Microb infect Dis. 1989; 8:233-7.
26. Triginer C, Robles A, Monforte R et al. Dosis unica diaria de aminoglucosidos en el paciente grave. Med Intensiva. 1994; 18:189-98.
27. Nicolau DP, Freeman CD, Belliveau PP et al. Experience with a once-daily aminoglycoside program administered to 2, 184 adult patients. Antimicrob Agents Chemother. 1995; 39:650-5.
28. Bourget P, Fernandez H, Delours C et al. Pharmacokinetics of tobramycin in pregnant women. Safety and efficacy of a once-daily dose regimen, J Clin Pharm Ther. 1991; 16:167-76.
29. Powell SH, Thompson WL, Luthe MA et al. Once-dail> vs continuous aminoglycoside dosing: efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin and tobramycin. J Infect Dis. 1983; 147:918-32.
30. Prins JM, Buller HR, Kuijper EJ et al. Once-daily gentamicin versus once-daily netilmicin in patients with serious intections - a randomized clinical trial. J Antimicrob Chemother. 1994; 33:823-35.
31. Beaucaire G, Leroy O, Beuscart C et al. Clinical and bacteriological efficacy, and practical aspects of amikacin given once daily for severe infections. J Antimicrob Chemother. 1991; 27(suppl C):91-103.
32. Craig WA, Redington J, Ebert SC. Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. J Antimicrob Chemother. 1991; 27(suppl C):29-40.
33. Dudley MN, Zinner SH. Single daily dosing of amikacin in an in-vitro model. J Antimicrob Chemother. 1991; 27(suppl C):15-9.
34. Blaser J. Efficacy of once- and thrice-daily dosing of aminoglycosides in in-vitro models of infection. J Antimicrob Chemother. 1991; 27(suppl C):21-8.
35. Fantin B, Pangon B, Potel G et al. Ceftriaxone - netilmicin combination in single-daily-dose treatment of experimental Escherichia coli endocarditis. Antimicrob Agents Chemother. 1989; 33:767-70.
36. Proctor L, Petty B, Thakor R et al. A study of potential vestibulotoxic effects of once daily versus thrice daily administration of tobramycin. Laryngoscope. 1987; 97:1443-9.
37. Petty BG, Baumgardner JY, Lietman PS. Comparison of the renal effects of single vs thrice daily dosing of tobramycin in healthy volunteers. Paper presented at Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, LA; 1986 Sep 28.
38. Krcmery V, Koza I, Mardiak J et al. Netilmicin plus ceftriaxone versus amikacin plus ceftriaxone in the treatment of infections in granulocytopenic patients. Chemotherapy. 1992; 38(1):74. Abstract.
39. Cudillo L, Masi M, Scimo MT et al. Ceftriaxone plus amikacin in a single daily dose as empiric antibiotic therapy in granulocytopenic patients. J Chemother. 1989; 1(6)413. Abstract.
40. Labovitz E, Levison ME, Kaye D. Single-dose daily gentamicin therapy in urinary tract infection. Antimicrob Agents Chemother. 1974; 6:465. Abstract.
41. Tulkens PM, Braun-Clerckx F, Donner J et al. Safety and efficacy of aminoglycosides once-a-day: experimental data and randomized, controlled evaluation in patients suffering from pelvic inflammatory disease. J Drug Dev. 1988; 1(suppl 3):71-82.
42. Tulkens PM. Efficacy and safety of aminoglycosides once-a-day: experimental and clinical data. Scand J Infect Dis. 1991; 74-249-57.
43. Maller R, Isaksson B, Nilsson L et al. A study of amikacin given once versus twice daily in serious infections, J Antimicrob Chemother. 1988; 22:75-9.
44. Maller R, Ahrne H. Eilard T et al. J Antimicrob Chemother. 1991; 27(suppl C):121-8.
45. Prins JM, Speelman P, Kuijper EJ et al. Once versus thrice daily administration of gentamicin in patients with serious infection-a randomized study. Paper presented at International Conference on Antimicrobial Agents and Chemotherapy. Montreal, Quebec, Canada; 1992 Jun 16.
46. Brulein V, Jacqmin P, Ibrahim S et al. Tolerance and efficacy of amikacin once-a-day (qd) vs twice-a-day (bid): a prospective, controlled study in 40 women suffering from pelvic inflammatory disease (PID). Paper presented at Fourth European Congress of Clinical Microbiology. Nice, France: 1989 Apr 17.
47. Ibrahim S, Derde MP, Kaufman L et al. Safety, pharmacokinetics and efficacy of once-a-day netilmicin and amikacin versus their conventional schedules in patients suffering from pelvic inflammatory disease. Ren Fail. 1990; 12:199-203.
48. Fauser AA, Lang E, Dolken G et al. Treatment of severe sepsis in bone marrow transplant recipients with teicoplanin in combination with beta-lactams and aminoglycosides. Infection. 1991; 19:195-200.
49. Krcmery V, Danisovicova A, Drgona L et al. Ceftriaxone versus ceftazidime plus aminoglycoside therapy for infections in patients with neutropenia after cytotoxic chemotherapy. Neoplasma. 1993; 40(2):103-5.
50. Rozdzinski E, Kern WV, Reichle A et al. Once-daily versus thrice-daily dosing of netilmicin in combination with β-lactam antibiotics as empirical therapy for febrile neutropenic patients. J Antimicrob Chemother. 1991; 31:585-98.
51. Hansen M, Achen F, Carstensen C et al. Once- versus thrice-daily dosing of netilmicin in febrile immunocompromised patients: a randomized, controlled study of efficacy and safety. J Drug Dev. 1988; 1(Suppl 3):119-24.
52. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Meet. 1993; 119:584-93.
53. Feld R, Rachlis A, Tuffnell P et al. Empiric therapy for infections in patients with granulocytopenia. Arch Intern Med. 1984; 144:1005-10.
54. Gibson J, Johnson L, Snowdown L et al. Single daily ceftriaxone and tobramycin in the empirical management of febrile neutropenic patients: a randomised trial. Int J Hematol. 1993; 58:63-72.
55. Leoni F, Ciolli S, Pascarella A et al. Ceftriaxone plus conventional or single-daily dose amikacin versus ceftazidime/amikacin as empiric therapy in febrile neutropenic patients. Chemotherapy. 1993; 39:147-52.
56. Klastersky J, Prévost JM, Meunier-Carpentier F et al. Comparative trial of single-dose versus twice-daily sisomicin in bacteriuric patients. J Clin Pharmacol. 1977; 17:520-8.
57. Trujillo H, Robledo J, Robledo C et al. Single daily dose amikacin in paediatric patients with severe gram-negative infections. J Antimicrob Chemother. 1991; 27(suppl C):141-7.
58. Kafetzis DA, Sianidou L, Vlachos E et al. Clinical and pharmacokinetic study of a single daily dose of amikacin in paediatric patients with severe gram-negative infections. J Antimicrob Chemother. 1991; 27(suppl C):105-12.
59. Viscoli C, Dudley M, Ferrea G et al. Serum concentrations and safety of single daily dosing of amikacin in children undergoing bone marrow transplantation. J Antimicrob Chemother. 1991; 27(suppl C):113-20.
60. Vigano A, Principi N, Brivio L et al. Comparison of 5 milligrams of netilmicin per kilogram of body weight once daily versus 2 milligrams per kilogram thrice daily for treatment of gram-negative pyelonephritis in children. Antimicrob Agents. Chemother. 1992; 36:1499-503.
61. Elhanan K, Siplovich L, Raz R. Gentamicin once-daily versus thrice-daily in children. J Antimicrob Chemother. 1995; 35:327-32.
62. Shankar A, Sharma SD. Gentamicin as once-daily dose therapy in recurrent unnary tract infections in children. Curr Ther Res. 1987; 41:599-603.
63. Langhendries JP, Battisti O, Bertrand JM et al. Once-a-day adminstration of amikacin in neonates: assessment of nephrotoxicity and ototoxicity. Dev Pharmacol Ther. 1993; 20:220-30.
64. Wagner BP, Pfeninger J. Once-daily dosing of netilmicin in neonatal and pediatric intensive care. Intensive Care Med. 1994; 20:365-7.
65. Heinenger U, Bowing B, Stehr K et al. A comparative trial of single versus triple dose of aminoglycosides in patients with cystic fibrosis and pulmonary exacerbation. Klin Padiatr. 1993; 205:18-22.
66. Frass M, Traindl O, Podolsky A et al. Comparison of once-daily versus thrice-daily dosage of netilmicin in critically ill patients. Wien Klin Wochenschr. 1991; 103(4):101-4.
67. Fan ST, Lau WY, Teoh-Chan CH et al. Once daily administration of netilmicin compared with thrice daily, both in combination with metronidazole, in gangrenous and perforated appendicitis. J Antimicrob Chemother. 1988; 22:69-74.
68. Tulkens PM. Pharmacokinetic and toxicological evaluation of a once-daily regimen versus conventional schedules of netilmicin and amikacin. J Antimicrob Chemother. 1991; 27(supplC):49-61.
69. Ter Braak EW, De Vries PJ, Bouter KP et al. Once-daily dosing regimen for aminoglycoside plus β-lactam combination therapy of serious bacterial infections: Comparative trial with netilmicin plus ceftriaxone. Am J Med. 1990; 89:58-65.
70. Sturm AW. Netilmicin in the treatment of gram-negative bacteremia: single daily versus multiple daily dosage. J Infect Dis. 1989; 159:931-7.
71. Hollender LP, Bahnini J, De Manzini N et al. A multicentric study of netilmicin once daily versus thrice daily in patients with appendicitis and other intra-abdominal infections. J Antimicrob Chemother. 1989; 23:773-83.
72. Maller R, Ahme H, Holmen C et al. Once versus twice-daily amikacin regimen: efficacy and safety in systemic gram-negative infections. J Antimicrob Chemother. 1993; 31:939-48.
73. Nordström L, Ringberg H, Cronberg S et al. Does administration of an aminoglycoside in a single daily dose affect its efficacy and toxicity? I Antimicrob Chemother. 1990; 25:159-73.
74. Prins JM, Büller HR, Kuijper EJ et al. Once versus thrice daily gentamicin in patients with serious infections. Lancet. 1993, 341:335-9.
75. Mauracher EH, Lau WY, Kartowisastro H et al. Comparison of once-daily and thrice-daily netilmicin regimens in serious systemic infections: a multicenter study in six Asian countries. Clin Ther. 1989; 11(5):604-13.
76. Van der Auwera P, Meunier F, Ibrahim S et al. Pharmacodynamic parameters and toxicity of netilmicin (6 milligrams/ kilogram/day) given once daily or in three divided doses to cancer patients with urinary tract infection. Antimicrob Agents Chemother. 1991; 35:640-7.
77. Giamarellou H, Yiallouros K, Petrikkos E et al. Comparative kinetics and efficacy of amikacin administered once or twice daily in the treatment of systemic gram-negative infections. J Antimicrob Chemother. 1991; 27(suppl C):73-9.
78. De Vries PJ, Verkooyen RP, Leguit P et al. Prospective randomized study of once-daily versus thrice-daily netilmicin regimens in patients with intraabdominal infections. Eur J Clin Microbiol Infect Dis. 1990; 9:161-8.
79. Marik PE, Lipman J, Kobilski S et al. A prospective randomized study comparing once- versus twice-daily amikacin dosing in critically ill adult and paediatric patients. J Antimicrob Chemother. 1991; 28:753-64.
80. Vanhaeverbeek M, Siska G, Douchamps J et al. Comparison of the efficacy and safety of amikacin once or twice-a-day in the treatment of severe gram-negative infections in the elderly. Int J Clin Pharmacol Ther Toxicol. 1993; 31 (3):153-6.
81. Cohen B, Saginur R, Clecner B et al. Double-blind comparative trial of once- vs. twice daily netilmicin therapy in severe acute urinary tract infections. Curr Ther Res. 1985; 38:880-4.
82. Mendes-da-Costa P, Kaufman L. Amikacin once daily plus metronidazole versus amikacin twice daily plus metronidazole in colorectal surgery. Hepatogastroenterology. 1992; 39:350-4.
83. Muijsken MA, Vreede RW, Van DiJk WC et al. A randomized clinical study of efficacy and safety of once-daily versus conventional dosing of netilmicin in patients with severe infections. J Drug Dev. 1988; 1(suppl 3):145-6.
84. Raz R, Adawi M, Romano S intravenous administration of gentamicin once daily versus thrice daily in adults. Eur J Clin Microbiol Infect Dis. 1995; 14:88-91.
85. Cohen J. Power analysis for the social sciences. New York: Academic Press; 1977.
86. Rotschafer JC, Rybak MJ. Single daily dosing of aminoglycosides: a commentary. Ann Pharmacother. 1994; 28:797-801.
87. Rodman DP, Maxwell AJ, McKnight JT. Extended dosage intervais for atninoglycosides. Am J Hosp Pharm. 1994; 51:2016-21.
88. Noone P, Parsons TMC, Pattison JR et al. Experience in monitoring gentamicin therapy during treatment of serious gram-negative sepsis. Br Med J. 1974; 1:477-81.
89. Barclay ML, Begg EJ, Hickling KG. What is the evidence for once-daily aminoglycoside therapy? Clin Pharmacokinet. 1994; 27(1):32-48.
90. Garrison MW, Zaske DE, Rotschafer JC. Aminoglycosides: another perspective. DICP Ann Pharmacother. 1990; 24:267-72.
91. Federspil P, Schatzle W, Tiester E. Pharmacokinetics and ototoxicity of gentamicin, tobramicin and amikacin. J Infect Dis. 1976; 134(suppl):200-5.
92. Zaske DE, Shikuma LR, Tholl DA. Aminoglycosides. In: Taylor WJ, Caviness MH, eds. A textbook for the clinical application of therapeutic drug monitoring. Irving, TX: Abbott Laboratories; 1986:285-319.
93. Ibrahim S, Lambricht P, Laurent G et al. Comparative analysis of the renal phospholipidosis and phospholipiduria induced by netilmicin (N), amikacin (A) and ipseamicin (I) in animals and humans. Paper presented at Interscience Conference on Antimicrobial Agents and Chemotherapy. Atlanta, GA; 1990 Oct 23.
94. Guay DRP. Netilmicin. Drug Intell Clin Pharm. 1983; 17:83-91.
95. Kahlmeter G, Dahlager JI. Aminoglycoside toxicity-a review of clinical studies published between 1975 and 1982. J Antimicrob Chemother. 1984; 13(suppl A):9-22.
96. Smith CR, Baughman KL, Edwards CQ et al. Controlled comparison of amikacin and gentamicin. N Engl J Med. 1977; 296:349-53.
97. Lerner AM, Reyes MP, Cone LA et al. Randomised, controlled trial of the comparative efficacy, auditory toxicity, and nephrotoxicity of tobramycin and netilmicin. Lancet. 1983; 1:1123-6.
98. Lerner SA, Schmitt B, Seligsohn R et al. Comparative study of ototoxicity and nephrotoxicity in patients randomly assigned to treatment with amikacin or gentamicin. Am J Med. 1986; 80(suppl 6B):98-104.
99. Konrad F, Wagner R, Neumeister B et al. Studies on drug monitoring in thrice and once daily treatment with aminoglycosides. Intensive Care Med. 1993; 19:215-20.
100. Hustinx WNM, Hoepelman IM. Aminoglycoside dosage regimens. Is once a day enough? Clin Pharmacokinet. 1993; 25:427-32.
101. Eisenberg JM, Koffer H, Click HA. What is the cost of nephrotoxicity associated with ammoglycosides? Ann Intern Med. 1987; 107:900-9.
102. Galløe AM, Graudal N, Christensen HR et al. Aminoglycosides: single or multiple daily dosing? A meta-analysis on efficacy and safety. Eur J Clin Pharmacol. 1995; 48:39-43.
103. Bates RD, Nahata MC. Once-daily administration of aminoglycosides. Ann Pharmacother. 1994; 28:757-66.